Top Highlights From the 2015 Society of Gynecologic Oncology Annual Meeting

Slideshow

This slide show features some of the top highlights from the 2015 Society of Gynecologic Oncology Annual Meeting, including a vaccine trial in ovarian cancer and a possible biomarker in advanced cervical cancer.

References:

1. Oh J, Barve M, Grosen EA, et al. Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 1.

2. Coleman RL, Brady MF, Herzog TJ, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 3.

3. Matulonis UA, Penson RT, Domchek SM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 14.

4. Fuh KC, Java J, Kapp DS, et al. Differences in presentation and survival of Asians versus Caucasians with ovarian cancer: A Gynecologic Oncology Group ancillary study of 7914 patients. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 9.

5. Tewari KS, Sill M, Monk BJ, et al. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 24.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.